S.Res. 510 · 118th Congress
A resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.
- Stage
- In committee
- Sponsor
- Elizabeth Warren
- Introduced
- 2023-12-14
- Latest action
- 2023-12-14 · Introduced in Senate
Summary
This resolution expresses the sense of the Senate that (1) policies governing access to medication abortion care should be based on scientific review by the Food and Drug Administration (FDA), and (2) the FDA has found mifepristone to be safe and effective for women seeking abortions.